NEWS & PUBLICATIONS
Advancing the Science of Next-Generation Bacterial Vaccines
TurboVax is committed to advancing bacterial vaccine innovation through scientific discovery, strategic collaborations, intellectual property development, and translational research.
This page highlights recent scientific publications, company news, conference presentations, funding milestones, and other important developments as TurboVax continues to evolve.
Featured Publications: The Scientific Foundation of the Turbo Platform
I. The Discovery
A foundational discovery demonstrating that residual TLR4 ligands naturally present in typhoid polysaccharide vaccines provide essential innate immune costimulatory signals required for optimal vaccine immunogenicity. This study challenged the long-held assumption that these vaccines are truly "unadjuvanted" and established the conceptual basis for rational innate immune design.
Scientific Impact
-
Identified the hidden source of innate immune stimulation in licensed typhoid vaccines.
-
Demonstrated that TLR4–MyD88 signaling is essential for optimal antibody responses.
-
Established the biological rationale for replacing undefined endotoxin with defined innate immune activation.
Alugupalli KR. TLR4 Ligands in Typhoid Vi Polysaccharide Subunit Vaccines Contribute to Immunogenicity. ImmunoHorizons. 2024 Jan 1;8(1):29-34. doi: 10.4049/immunohorizons.2300085. PMID: 38180344; PMCID: PMC10832388
II. The Translation
This study translated the mechanistic discovery into a practical vaccine technology by demonstrating that the Turbo platform significantly enhances the magnitude, durability, and protective efficacy of both conjugated and unconjugated typhoid vaccines across infant, adult, aged, and genetically diverse animal models.
Scientific Impact
-
Demonstrated broad enhancement of antibody responses across multiple vaccine formulations.
-
Improved long-term protection and bacterial clearance in challenge models.
-
Showed robust activity under antigen-limiting conditions, supporting dose-sparing strategies.
-
Established Turbo as a practical platform for improving bacterial polysaccharide vaccines.
III. Platform Expansion
This publication extended the Turbo platform beyond typhoid by demonstrating that defined TLR4-mediated innate immune activation enhances licensed quadrivalent meningococcal conjugate vaccines. The work establishes Turbo as a broadly applicable platform technology rather than a vaccine-specific solution.
Scientific Impact
• Demonstrated improved immune responses to all four meningococcal serogroups.
• Reduced dependence on multiple booster immunizations.
• Enhanced vaccine performance in infant, adult, and aged animal models.
• Validated Turbo as a scalable platform for multiple bacterial glycoconjugate vaccines.
IV. Mechanistic Validation
This study defines the molecular mechanism underlying the Turbo platform and demonstrates how rational activation of innate immune signaling produces stronger, broader, and more durable antibody responses than conventional adjuvants. By identifying the specific immune pathways responsible for Turbo's activity, this work provides the mechanistic foundation for applying the platform across bacterial glycoconjugate vaccines.
Scientific Impact
-
Defined the molecular mechanism responsible for Turbo adjuvanticity through the TLR4–MyD88 signaling pathway.
-
Demonstrated that Turbo induces balanced class switching to all IgG subclasses, affinity maturation, and long-lived plasma cells associated with durable immunity.
-
Showed that Turbo operates through immune pathways distinct from alum and does not depend on inflammasome activation.
-
Identified CD40 and CD86 costimulatory signaling as critical components of Turbo-mediated enhancement of glycoconjugate vaccine responses.
-
Demonstrated that Turbo formulations based on both TLR4 and TLR2 agonists retain broad adjuvant activity, establishing a flexible platform for future vaccine development.
